|
Indications and Dosage
Intravenous
Susceptible infections Adult: As sulfate: 1-2 g every 12 hr via IV inj over 3-5 minutes or infuse over 20-30 minutes.
|
||||||||
|
Renal Impairment
Loading dose: 1-2 g followed by a maintenance dose adjusted according to CrCl.
|
||||||||
|
Contraindications
Hypersensitivity; porphyria.
|
||||||||
|
Special Precautions
Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation.
|
||||||||
|
Adverse Reactions
Rash, pruritus, urticaria; nausea, vomiting, abdominal pain, diarrhoea; increased plasma levels of ASAT, ALAT, gamma-GT, LDH, bilirubin and/or alkaline phosphatase; interstitial nephritis, acute renal failure; thrombocytopaenia, eosinophilia, haemolytic anaemia, neutropaenia, agranulocytosis; thrombophloebitis, pain at Inj site; convulsions, fever; haemorrhage.
Potentially Fatal: Pseudomembranous colitis. |
||||||||
|
Drug Interactions
Reduced clearance with probenecid.
|
||||||||
|
Lab Interference
Interferes with Jaffe method of creatinine conc measurement in determining renal function.
|
||||||||
|
Action
Description:
Mechanism of Action: Cefpirome binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Pharmacokinetics: Distribution: Widely distributed into body tissues and fluids; enters breast milk. Protein-binding: 10% Excretion: Mainly by the kidneys via the urine (80-90% as unchanged); significantly removed by haemodialysis; 2 hrs (elimination half-life); prolonged in renal impairment. |
||||||||
|
Storage
Store below 25°C.
|
||||||||
|
MIMS Class
|
Sign Out
